DOI: 10.1055/s-00000004

Aktuelle Neurologie

References

Cohen JA, Coles AJ, Arnold DL. et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial.

Lancet 2012;
380: 1819-1828

Download Bibliographical Data

Search in:
Access: